keyword
MENU ▼
Read by QxMD icon Read
search

Carcinoid

keyword
https://www.readbyqxmd.com/read/29145657/the-utility-of-blood-neuroendocrine-gene-transcript-measurement-in-the-diagnosis-of-bronchopulmonary-neuroendocrine-tumours-and-as-a-tool-to-evaluate-surgical-resection-and-disease-progression
#1
Pier Luigi Filosso, Mark Kidd, Matteo Roffinella, Anna Lewczuk, Kyung-Min Chung, Agnieszka Kolasinska-Cwikla, Jaroslaw Cwikla, Anna Lowczak, Anna Doboszynska, Anna Malczewska, Maria Catalano, Valentina Zunino, Monica Boita, Emanuela Arvat, Riccardo Cristofori, Francesco Guerrera, Alberto Oliaro, Margot Tesselaar, Wieneke Buikhuisen, Beata Kos-Kudla, Mauro Papotti, Lisa Bodei, Ignat Drozdov, Irvin Modlin
OBJECTIVES: The management of bronchopulmonary neuroendocrine tumours (BPNETs) is difficult, since imaging, histology and biomarkers have a limited value in diagnosis, predicting outcome and defining therapeutic efficacy. We evaluated a NET multigene blood test (NETest) to diagnose BPNETs, assess disease status and evaluate surgical resection. METHODS: (i) Diagnostic cohort: BP carcinoids (n = 118)-typical carcinoid, n = 67 and atypical carcinoid, n = 51; other lung NEN (large-cell neuroendocrine carcinoma and small-cell lung carcinoma, n = 13); adenocarcinoma, (n = 26); squamous cell carcinoma (n = 23); controls (n = 90) and chronic obstructive pulmonary disease (n = 18)...
November 13, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/29142475/predictive-factors-associated-with-carcinoid-syndrome-in-patients-with-gastrointestinal-neuroendocrine-tumors
#2
Beilei Cai, Michael S Broder, Eunice Chang, Tingjian Yan, David C Metz
AIM: To discover unknown factors associated with carcinoid syndrome (CS) with the goal of earlier diagnosis of CS. METHODS: In this retrospective case-control study using United States administrative claims, patients (≥ 18 years) newly-diagnosed with gastrointestinal neuroendocrine tumors (GI NETs) without CS (controls) were exactly matched to patients with CS (cases) based on NET diagnosis date at a 3-to-1 ratio. Study index date was first CS diagnosis (controls: same distance from NET diagnosis as cases)...
October 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29141071/usefulness-of-total-12-lead-qrs-voltage-as-a-clue-to-diagnosis-of-patients-with-cardiac-sarcoidosis-severe-enough-to-warrant-orthotopic-heart-transplant
#3
William C Roberts, Tiffany M Becker, Shelley A Hall
Importance: Severe heart failure caused by cardiac sarcoidosis is difficult to diagnosis without biopsy. Objective: To assess whether total electrocardiographic 12-lead QRS voltage may be a clue to diagnosis. Design, Setting, Participants: Case-series study with cases collected at Baylor University Medical Center at Dallas, Dallas, Texas, from January 13, 2005, to January 24, 2017. The clinical records of 16 patients with severe heart failure caused by cardiac sarcoidosis were studied...
November 15, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/29138755/paraneoplastic-hepatopathy-associated-with-gastrointestinal-carcinoid
#4
Dhruv Mehta, Priyanka Chugh, Lavneet Chawla, Daniela Jodorkovsky
Paraneoplastic hepatopathy has been reported with various malignancies, most commonly with renal cell cancer. This non-metastatic hepatic dysfunction in such malignancies is known as Stauffer syndrome. We describe a 61-year-old man who presented with symptoms of bowel obstruction with marked cholestasis and high levels of alkaline phosphatase and bilirubin. Imaging revealed an unremarkable liver and a mass in the ileocecal valve with mesenteric lymphadenopathy. Biopsies were consistent with a carcinoid tumor...
2017: ACG Case Reports Journal
https://www.readbyqxmd.com/read/29132704/extent-of-resection-and-lymph-node-assessment-for-clinical-stage-t1an0m0-typical-carcinoid-tumors
#5
Lisa M Brown, David T Cooke, James R Jett, Elizabeth A David
BACKGROUND: The optimal extent of lung resection and lymph node (LN) assessment for surgical treatment of clinical stage T1aN0M0 typical carcinoid tumors is unclear. Using a cohort including only these patients, we aimed to determine the impact of extent of lung resection and LN assessment on overall survival. METHODS: Patients undergoing lobectomy or sublobar resection for clinical stage T1aN0M0 intraparenchymal typical carcinoid tumor were identified in the National Cancer Data Base from 1998 to 2012...
November 11, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/29124912/metastatic-medullary-thyroid-carcinoma-or-calcitonin-secreting-carcinoid-tumor-of-lung-a-diagnostic-dilemma-in-a-patient-with-lung-mass-and-thyroid-nodule
#6
Shifteh Vahidi, Jimmie Stewart, Khalid Amin, Emilian Racila, Faqian Li
Calcitonin-secreting neuroendocrine tumors are rare and have been reported in literature as case reports or case series in various organs including lung, pancreas, larynx, bladder, and ovary. These tumors have similar cytologic features and immunohistochemical profile to medullary thyroid carcinoma and thus it is difficult to distinguish them, especially when calcitonin-secreting neuroendocrine tumors are intermediate or higher grade and there is a mass lesion in the thyroid gland. Here, we report a rare case of calcitonin secreting atypical carcinoid tumor of the lung in a patient with thyroid nodule...
November 10, 2017: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/29120923/carcinoid-syndrome-recent-advances-current-status-and-controversies
#7
Tetsuhide Ito, Lingaku Lee, Robert T Jensen
PURPOSE OF REVIEW: To review recent advances and controversies in all aspects of carcinoid-syndrome. RECENT FINDINGS: Over the last few years there have been a number of advances in all aspects of carcinoid syndrome as well as new therapies. These include new studies on its epidemiology which demonstrate it is increasing in frequency; increasing insights into the pathogenesis of its various clinical manifestations and into its natural history: definition of prognostic factors; new methods to verify its presence; the development of new drugs to treat its various manifestations, both initially and in somatostatin-refractory cases; and an increased understanding of the pathogenesis, natural history and management of carcinoid heart disease...
November 7, 2017: Current Opinion in Endocrinology, Diabetes, and Obesity
https://www.readbyqxmd.com/read/29116005/composite-intestinal-adenoma-microcarcinoid-in-the-colon-and-rectum-a-case-series-and-historical-review
#8
Mi-Jung Kim, Eun-Jung Lee, Do Sun Kim, Doo Han Lee, Eui Gon Youk, Hyun-Jung Kim
BACKGROUND: Composite intestinal adenoma-microcarcinoid (CIAM) is a rare colorectal lesion that mostly comprises a conventional adenomatous component with a minute proportion of neuroendocrine (NE) component. Although microcarcinoids are well-recognized in the setting of chronic inflammatory disorders of the gastrointestinal tract, large intestinal microcarcinoids associated with intestinal adenoma are exceedingly rare and their clinicopathologic characteristics are yet to be elucidated...
November 7, 2017: Diagnostic Pathology
https://www.readbyqxmd.com/read/29114468/classification-of-pulmonary-neuroendocrine-tumors-new-insights
#9
REVIEW
Giuseppe Pelosi, Angelica Sonzogni, Sergio Harari, Adriana Albini, Enrica Bresaola, Caterina Marchiò, Federica Massa, Luisella Righi, Gaia Gatti, Nikolaos Papanikolaou, Namrata Vijayvergia, Fiorella Calabrese, Mauro Papotti
Neuroendocrine tumors of the lung (Lu-NETs) embrace a heterogeneous family of neoplasms classified into four histological variants, namely typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC). Defining criteria on resection specimens include mitotic count in 2 mm(2) and the presence or absence of necrosis, alongside a constellation of cytological and histological traits including cell size and shape, nuclear features and overall architecture...
October 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29112233/neuroendocrine-tumors-and-fibrosis-an-unsolved-mystery
#10
REVIEW
Faidon-Marios Laskaratos, Krista Rombouts, Martyn Caplin, Christos Toumpanakis, Christina Thirlwell, Dalvinder Mandair
Neuroendocrine tumors are a heterogeneous group of slow-growing neoplasms arising mainly from the enterochromaffin cells of the digestive and respiratory tract. Although they are relatively rare, their incidence is rising. It has long been observed that they often are associated with the development of fibrosis, both local and distant. Fibrotic complications, such as carcinoid heart disease and mesenteric desmoplasia, may lead to considerable morbidity or even affect prognosis. The elucidation of the pathophysiology of fibrosis would be of critical importance for the development of targeted therapeutic strategies...
November 7, 2017: Cancer
https://www.readbyqxmd.com/read/29109490/lower-extremity-vasospasm-caused-by-carcinoid-syndrome
#11
Wala Ben Kridis, Zeinab Guermazi, Héla Mnif, Nabil Toumi, Afef Khanfir, Tahia Boudawara, Mounir Frikha
No abstract text is available yet for this article.
November 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29105026/metastatic-non-small-cell-lung-carcinoma-a-mimic-of-primary-breast-carcinoma-case-series-and-literature-review
#12
Rola H Ali, Catalin Taraboanta, Tareq Mohammad, Malcolm M Hayes, Diana N Ionescu
Metastatic tumors to the breast are rare but constitute a major diagnostic dilemma. Of these, non-mammary carcinomatous metastases to the breast are particularly challenging and, without a clinical history, may be extremely difficult to distinguish from primary breast carcinoma (PBC). We specifically studied metastatic tumors of pulmonary origin, as the lung is one of the major primary sites for carcinomatous metastasis to breast. Sixteen metastatic lung tumors to the breast were identified in our archives between 1996 and 2017 including 12 non-small cell lung carcinomas (NSCLC), one large-cell neuroendocrine, one atypical carcinoid, and two small-cell carcinomas...
November 5, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/29103583/expanded-criteria-for-debulking-of-liver-metastasis-also-apply-to-pancreatic-neuroendocrine-tumors
#13
Rosemary E Morgan, SuEllen J Pommier, Rodney F Pommier
BACKGROUND: Recently, there has been a move toward decreasing the threshold for liver debulking for metastatic carcinoid tumors from 90% to 70%. The debulking threshold and factors that predict outcomes of liver debulking operations specifically among pancreatic neuroendocrine tumors are not well defined. METHODS: Records of patients with pancreatic neuroendocrine tumors undergoing liver debulking with a threshold of 70% from 2006 to 2016 were reviewed. Extrahepatic metastases and positive margins by enucleation were allowed...
November 2, 2017: Surgery
https://www.readbyqxmd.com/read/29100390/flna-is-implicated-in-pulmonary-neuroendocrine-tumors-aggressiveness-and-progression
#14
Eleonora Vitali, Ilena Boemi, Lorenzo Rosso, Valeria Cambiaghi, Pierluigi Novellis, Giovanna Mantovani, Anna Spada, Marco Alloisio, Giulia Veronesi, Stefano Ferrero, Andrea G Lania
Pulmonary neuroendocrine tumors (PNTs) comprise different neoplasms, ranging from low grade carcinoids to the highly malignant small cell lung cancers. Several studies identified the cytoskeleton protein Filamin A (FLNA) as determinant in cancer progression and metastasis, but the role of FLNA in PNT aggressiveness and progression is still unknown. We evaluated FLNA expression in PNTs with different grade of differentiation, the role of FLNA in cell proliferation, colony formation, angiogenesis, cell adhesion and migration in PNT cell line (H727 cells) and primary cultures and the possible interaction between FLNA and Rap1-GTPase...
September 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/29092118/carcinoid-valve-disease-a-case-report-and-review
#15
Daniel Heikali, Nelson Chang, Ramin Tabibiazar
In patients with carcinoid syndrome, the development of carcinoid valve disease typically carries an unfavorable prognosis. We present the case of a patient with significant valvular dysfunction secondary to carcinoid valve disease. Valve replacement surgery was complicated by the development of prosthetic valve degeneration, ultimately requiring percutaneous valve implantation in a valve-in-valve fashion. The technical details of the case, as well as a review of carcinoid valve disease, including its pathophysiology, clinical manifestations, diagnostic features and management considerations, are presented...
May 2017: Journal of Heart Valve Disease
https://www.readbyqxmd.com/read/29081927/atelectasis-in-pediatrics-a-case-of-carcinoid-tumor
#16
Cláudia Vaz Guerreiro, Paula Ornelas, Luísa Pereira, Nuno Abecasis, Maria Teresa Almodovar
Carcinoid pulmonary tumors occur in the fourth to sixth decades of life. Usually, typical carcinoid arise a decade earlier when compared to atypical carcinoid (45 years and 55 years, respectively). Typical carcinoid tumors are the most common primary lung neoplasm in children and late adolescents, but there are less than 40 cases described in the literature. The clinical presentation is nonspecific and usually the symptoms are due to bronchial obstruction, sometimes with recurrent pneumonia. Its rarity may delay diagnosis but in most cases a favorable course after treatment is observed...
October 3, 2017: Rare Tumors
https://www.readbyqxmd.com/read/29080935/echocardiography-in-functional-midgut-neuroendocrine-tumors-when-and-how-often
#17
REVIEW
Javier G Castillo, Tara Naib, Jerome S Zacks, David H Adams
The management of patients with midgut neuroendocrine tumors (MNET) is rapidly evolving. Current preoperative detection rates of primary tumor sites are higher than ever and progression-free survival in patients with already advanced disease is expanding due to the implementation of novel efficacious treatment strategies. This survival benefit may potentially translate into a need for a multidisciplinary approach to an even more heterogenous variety of clinical conditions, among these, carcinoid syndrome (CS) and carcinoid heart disease (CHD)...
October 28, 2017: Reviews in Endocrine & Metabolic Disorders
https://www.readbyqxmd.com/read/29076658/fine-needle-aspiration-cytology-of-hepatic-metastases-of-neuroendocrine-tumors-a-20-year-retrospective-single-institutional-study
#18
Omer A M Saeed, Harvey Cramer, Xiaoyan Wang, Howard H Wu
BACKGROUND: Fine needle aspiration (FNA) is considered an excellent technique for documenting metastatic neuroendocrine tumors (NETs). This study aims to evaluate the accuracy of FNA in diagnosing metastatic NETs to the liver and determining the grade and origin of these metastases. METHODS: Our laboratory information system was searched from 1997 to 2016 to identify all cases of metastatic NETs to the liver that were sampled by FNA. The cytopathology and surgical pathology reports as well as the patients' electronic medical records were reviewed...
October 27, 2017: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/29074312/understanding-the-patient-experience-with-carcinoid-syndrome-exit-interviews-from-a-randomized-placebo-controlled-study-of-telotristat-ethyl
#19
Lowell Anthony, Claire Ervin, Pablo Lapuerta, Matthew H Kulke, Pamela Kunz, Emily Bergsland, Dieter Hörsch, David C Metz, Janice Pasieka, Nick Pavlakis, Marianne Pavel, Martyn Caplin, Kjell Öberg, John Ramage, Emily Evans, Qi Melissa Yang, Shanna Jackson, Karie Arnold, Linda Law, Dana B DiBenedetti
PURPOSE: Telotristat ethyl, an oral tryptophan hydroxylase inhibitor, is intended to treat carcinoid syndrome by reducing serotonin production. Telotristat ethyl was evaluated in TELESTAR, a Phase III study for patients who had carcinoid syndrome with at least 4 bowel movements (BMs) per day and who were receiving somatostatin analogue therapy. This interview substudy was conducted to provide insight into the patient experience in TELESTAR and to help understand whether reductions in BM frequency (the primary end point) and other symptoms were clinically meaningful...
October 23, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29074099/efficacy-and-safety-of-long-acting-pasireotide-or-everolimus-alone-or-in-combination-in-patients-with-advanced-carcinoids-of-the-lung-and-thymus-luna-an-open-label-multicentre-randomised-phase-2-trial
#20
Piero Ferolla, Maria Pia Brizzi, Tim Meyer, Wasat Mansoor, Julien Mazieres, Christine Do Cao, Hervé Léna, Alfredo Berruti, Vincenzo Damiano, Wieneke Buikhuisen, Henning Grønbæk, Catherine Lombard-Bohas, Christian Grohé, Vincenzo Minotti, Marcello Tiseo, Javier De Castro, Nicholas Reed, Gabriella Gislimberti, Neha Singh, Miona Stankovic, Kjell Öberg, Eric Baudin
BACKGROUND: There are no data from prospective studies focused exclusively on patients with advanced lung and thymic carcinoids. We aimed to assess the efficacy and safety of long-acting pasireotide and everolimus, administered alone or in combination, in patients with advanced carcinoids of the lung or thymus. METHODS: LUNA was a prospective, multicentre, randomised, open-label, phase 2 trial of adult patients (aged >18 years) with advanced (unresectable or metastatic), well differentiated carcinoid tumours of the lung or thymus, with radiological progression within 12 months before randomisation, and a WHO performance status of 0-2...
October 23, 2017: Lancet Oncology
keyword
keyword
13797
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"